News

Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Valneva announced positive initial booster data and final Phase 1 data for its leading, unique Lyme disease vaccine candidate VLA15. To investigate…

Read more

Vienna BioCenter at the ball of sciences

On January 26th 2019, the scientific community from Austria (and abroad) got together in the glamorous setting of the Vienna City Hall for the 5th…

Read more

Open Access to selected VBCF services until exploitation of available funds!

Take advantage of the possibility to get selected VBCF services for free! The open access is supported by the project RIAT-CZ, programme INTERREG V-A…

Read more

10 Million Euros for Access to European Proteomics Facilities

The European Union has awarded 10 million Euros to a consortium of 18 research groups that work with mass spectrometry-based proteomics, including the…

Read more

Obituary: Andreas Weith (1953 to 2019), former IMP Group Leader

The IMP is sad to share the news of the sudden and untimely passing of Andreas Weith who was a Group Leader at the IMP from 1990 to 1997.

Read more

Official opening of the new Electron Microscope Glacios

It is our pleasure to invite you to the official opening of our new Electron Microscope (Glacios) and an Open House of the EM Facility:

 

This Friday…

Read more

Valneva Announces New $59 Million IXIARO® Supply Contract with US Government

Valneva announced the signing of a new $59 million contract with the U.S. government Department of Defense for the supply of its Japanese encephalitis…

Read more

Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Valneva confirmed its revenue and product sales guidance for 2018 and provided initial product sales guidance for 2019.

Read more

Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting…

Read more

The biomechanics of vascular ageing

Cardiovascular Diseases (CVD) lead to atherosclerosis and heart failure and are prevalent age-related illnesses in humans. In a new study, published…

Read more

Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test

Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency, and initiates set-up of R&D and service…

Read more

Valneva Announces its Intention to Delist from the Vienna Stock Exchange

Valneva announced that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science…

Read more